Polypid To Report Third Quarter 2026 Financial Results And Operational Highlights On November 11, 2026
| Date: | Wednesday, November 11, 2026 |
| Time: | 8:30 AM Eastern Time |
| Conference Call: | |
| Webcast: |
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid's lead product, D-PLEX100, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit and follow us on Twitter (X) and LinkedIn.
Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
...
Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
...

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment